Some breast cancer drugs can penetrate the blood-brain barrier (BBB), but they have not been very effective against brain metastases, whereas other, more effective anti-breast cancer drugs cannot penetrate the BBB at all. Researchers have now used a new approach to selectively permeabilize the BBB at sites of brain metastases, even those 200 times smaller than currently detectable in the clinic.